Details : Commonly involves immune suppression within the urinary tract. 

Research Status : GcMAF (Gc protein-derived macrophage-activating factor) is a type of immunotherapy that has been explored for its potential benefits in treating various cancers, including bladder cancer. Here are 12 reasons how GcMAF could benefit in the treatment of bladder cancer patients: 

1. Immune System Activation : GcMAF activates macrophages, which are crucial for attacking cancer cells.
2. Reduction of Nagalase Activity : Cancer cells produce nagalase, an enzyme that inhibits the immune system. GcMAF can reduce nagalase levels, potentially restoring immune function.
3. Anti-Angiogenic Effects : GcMAF has the ability to inhibit the formation of new blood vessels that tumors need to grow.
4. Enhanced Phagocytosis : Activated macrophages can better engulf and destroy cancer cells.
5. Improved Immune Surveillance : GcMAF can enhance the body’s ability to detect and eliminate cancer cells.
6. Reduction of Tumor Burden : By activating macrophages, GcMAF can help reduce the size and spread of tumors.
7. Support for Conventional Therapies : GcMAF can enhance the effectiveness of traditional treatments like chemotherapy and radiation.
8. Minimal Side Effects : GcMAF therapy has been reported to have minimal adverse effects and no lasting side effects, compared to conventional cancer treatments
9. Potential for Long-Term Remission : Studies suggest that GcMAF can lead to long-term remission in cancer patients.
10. Improved Quality of Life : Patients receiving GcMAF have reported better overall health and fewer cancer-related symptoms.
11. Reduction in Metastasis : GcMAF  helps prevent the spread of cancer to other parts of the body.
12. Personalized Treatment : GcMAF therapy can be tailored to individual patients based on their specific immune profiles.